PHILADELPHIA, Pa. — PCI Pharma Services is investing more than $1 billion to expand its sterile fill-finish and drug-device combination capabilities across the U.S. and Europe, as pharmaceutical companies increasingly prioritize domestic manufacturing and supply chain resilience.
The contract development and manufacturing organization said the multi-year investment will enhance its ability to support drug development, clinical trial supply, and commercial manufacturing, particularly for complex biologics and advanced drug delivery systems.
At the center of the expansion is a $100 million project at the company’s San Diego facility, where a new high-speed isolator filling line for prefilled syringes and cartridges is expected to be operational in the first half of 2028. The addition will more than double the site’s existing capacity.
PCI is also expanding its Bedford, New Hampshire campus, where a new sterile fill-finish line capable of producing up to 300,000 vials per batch is being commissioned. The site is expected to reach annual production capacity of about 33 million vials, positioning it among the most advanced facilities of its kind in the U.S.
Across its U.S. operations, the company has invested in automated visual inspection systems that support production of more than 70 million prefilled syringes and cartridges and 40 million vials annually.
Beyond manufacturing, PCI is expanding its drug-device combination assembly and packaging capabilities. Facilities in Philadelphia and Rockford, Illinois, are undergoing upgrades to increase capacity for autoinjector production, with total U.S. capacity expected to exceed 250 million units per year by 2027.
The company is also launching new Development Centers of Excellence in Bedford and León, Spain, focused on formulation, analytical services, and advanced injectable technologies. The Bedford center is expected to open in May, followed by the León site in June.
“The pharmaceutical industry is at an inflection point, with manufacturers seeking trusted US-based partners to provide scale, expedience, and established quality and compliance track records to support the development and commercialization of next-generation treatments,” said Salim Haffar, chief executive officer of PCI Pharma Services. “Backed by over $1 billion in global infrastructure investment and decades of operational expertise, PCI’s multi-year journey to bolster its domestic manufacturing footprint allows us to meet growing customer demand for innovative drug product and drug delivery solutions, toward the evergreen goal of delivering life-changing therapies to patients.”
